Medicare Benefits Schedule - Note TN.1.26

Search Results for Note TN.1.26

View Related Items

Category 3 - THERAPEUTIC PROCEDURES

TN.1.26

In vitro processing with cryopreservation of bone marrow or peripheral blood

MBS rebates for autologous stem cell transplantation are only available for patients with aggressive malignancy or one which has proven refractory to prior treatment. Patients should also meet the criteria for treatment according to:

Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy

Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

In addition, the treatment should be authorised and overseen by a multidisciplinary cancer team.

Related Items: 13760


Related Items

Category 3 - THERAPEUTIC PROCEDURES

13760

13760 - Additional Information

Item Start Date:
01-Jul-1996
Description Updated:
01-Nov-2020
Schedule Fee Updated:
01-Jul-2024

In vitro processing with cryopreservation of bone marrow or peripheral blood, for autologous stem cell transplantation for a patient receiving high‑dose chemotherapy for management of:

(a) aggressive malignancy; or

(b) malignancy that has proven refractory to prior treatment

Fee: $868.80 Benefit: 75% = $651.60 85% = $770.10

(See para TN.1.26 of explanatory notes to this Category)


Legend

  • Assist - Addition/Deletion of (Assist.)
  • Amend - Amended Description
  • Anaes - Anaesthetic Values Amended
  • Emsn - EMSN Change
  • Fee - Fee Amended
  • Renum - Item Number Change (renumbered)
  • New - New Item
  • NewMin - New Item (previous Ministerial Determination)
  • Qfe - QFE Change